RU2316564C2 - Специфические антитела человека для избирательной терапии рака - Google Patents

Специфические антитела человека для избирательной терапии рака Download PDF

Info

Publication number
RU2316564C2
RU2316564C2 RU2003123100/13A RU2003123100A RU2316564C2 RU 2316564 C2 RU2316564 C2 RU 2316564C2 RU 2003123100/13 A RU2003123100/13 A RU 2003123100/13A RU 2003123100 A RU2003123100 A RU 2003123100A RU 2316564 C2 RU2316564 C2 RU 2316564C2
Authority
RU
Russia
Prior art keywords
peptide
molecule
polypeptide according
cells
binding
Prior art date
Application number
RU2003123100/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2003123100A (ru
Inventor
Йошевед ХАГАЙ (IL)
Йошевед ХАГАЙ
Жанет ЛАЗАРОВИЦ (IL)
Жанет ЛАЗАРОВИЦ
Рашель ГИ (IL)
Рашель ГИ
Орли ЛИПШИЦ (IL)
Орли ЛИПШИЦ
Эстер ЗАНТОН (IL)
Эстер ЗАНТОН
Авигдор ЛЕВАНОН (IL)
Авигдор ЛЕВАНОН
Даниэль ПЛАКСИН (IL)
Даниэль ПЛАКСИН
Тувиа ПЕРЕЦ (IL)
Тувиа ПЕРЕЦ
Original Assignee
Сейвиент Фармасьютикэлс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сейвиент Фармасьютикэлс, Инк. filed Critical Сейвиент Фармасьютикэлс, Инк.
Publication of RU2003123100A publication Critical patent/RU2003123100A/ru
Application granted granted Critical
Publication of RU2316564C2 publication Critical patent/RU2316564C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2003123100/13A 2000-12-29 2001-12-31 Специфические антитела человека для избирательной терапии рака RU2316564C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
US09/751,181 2000-12-29

Publications (2)

Publication Number Publication Date
RU2003123100A RU2003123100A (ru) 2005-03-10
RU2316564C2 true RU2316564C2 (ru) 2008-02-10

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003123100/13A RU2316564C2 (ru) 2000-12-29 2001-12-31 Специфические антитела человека для избирательной терапии рака

Country Status (15)

Country Link
EP (1) EP1353937A4 (zh)
JP (1) JP2004524023A (zh)
KR (1) KR20030091952A (zh)
CN (1) CN100374456C (zh)
AU (1) AU2002246737B2 (zh)
BR (1) BR0116763A (zh)
CA (1) CA2433227A1 (zh)
CZ (1) CZ20031983A3 (zh)
HU (1) HUP0400775A2 (zh)
IL (1) IL156690A0 (zh)
MX (1) MXPA03005944A (zh)
NZ (1) NZ527173A (zh)
PL (1) PL365758A1 (zh)
RU (1) RU2316564C2 (zh)
WO (1) WO2002059264A2 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491427A1 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
CA2531283A1 (en) * 2003-06-30 2005-01-20 Bio-Technology General (Israel) Ltd. Specific human antibodies
MX2007013304A (es) 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
WO2010078916A1 (en) * 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
US9211344B2 (en) * 2010-07-09 2015-12-15 Affibody Ab Polypeptides
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
ES2731876T3 (es) * 2014-10-23 2019-11-19 Singh Molecular Medicine Llc Anticuerpos de dominio sencillo contra antígenos intracelulares
CA2970255A1 (en) * 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
CN114195882A (zh) * 2015-10-01 2022-03-18 圣拉斐尔医院有限公司 Tcr及其用途
AU2016358296B2 (en) * 2015-11-19 2020-05-21 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
DK4050034T3 (da) * 2016-09-14 2024-06-03 Teneoone Inc Cd3-bindende antistoffer
WO2022103961A1 (en) * 2020-11-13 2022-05-19 Prometheus Biosciences, Inc. Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
BR9806793A (pt) * 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Моноклональные антитела. /Под ред. Р.Г.КЕННЕТА с соавт. - М.: Медицина, 1983, с.107. *

Also Published As

Publication number Publication date
CZ20031983A3 (cs) 2005-07-13
NZ527173A (en) 2006-03-31
HUP0400775A2 (en) 2007-05-02
KR20030091952A (ko) 2003-12-03
JP2004524023A (ja) 2004-08-12
AU2002246737B2 (en) 2007-03-01
CN100374456C (zh) 2008-03-12
WO2002059264A2 (en) 2002-08-01
WO2002059264A3 (en) 2003-03-06
IL156690A0 (en) 2004-01-04
EP1353937A2 (en) 2003-10-22
MXPA03005944A (es) 2005-04-29
CN1551886A (zh) 2004-12-01
EP1353937A4 (en) 2005-04-13
BR0116763A (pt) 2004-03-09
PL365758A1 (en) 2005-01-10
RU2003123100A (ru) 2005-03-10
CA2433227A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
RU2316564C2 (ru) Специфические антитела человека для избирательной терапии рака
RU2376316C2 (ru) Человеческие антитела против человеческого 4-1вв (cd137)
RU2317999C2 (ru) SCFV ПРОТИВ EGFRvIII С УЛУЧШЕННОЙ ЦИТОТОКСИЧНОСТЬЮ И ВЫХОДОМ, ИММУНОТОКСИНЫ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
Raag et al. Single‐chain fvs
JP2007526880A5 (zh)
HRP20130077A2 (hr) Humana monoklonalna protutjela za ctla-4
RU2487723C2 (ru) Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток
TNSN06087A1 (en) Therapeutic binding molecules
FI3433280T3 (fi) Proteaasin aktivoimia t-solubispesifisiä molekyylejä
KR900700134A (ko) Il-2 수용체-특이적 키메릭 항체
WO2019030240A1 (en) ANTIBODIES BINDING TO A LINEAR HUMAN CS1 EPITOPE
Piazza et al. Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody
AR035581A1 (es) Anticuerpos para il-1beta humana
RU2003133973A (ru) Анти-человечно-яичниково-карциномное и анти-человечно-анти-cd-3, биспецифическое антитело
PE20060817A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
JP2008532949A5 (zh)
WO2002072832A3 (en) Therapeutic binding molecules
JP2005510246A5 (zh)
CA2441845A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
Xiong et al. Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding
KR101828794B1 (ko) 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 항체
Wong et al. Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells
WO2018147960A1 (en) Extension sequences for diabodies
RU2005121669A (ru) Анти-nogo антитела ("11с7") и их фармацевтическое использование
DE10021678A1 (de) Antikörperkonstrukte mit variablen Regionen

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080101